Sixth Test in Theradiag's Monitoring Range Launched in the USA

CROISSY-BEAUBOURG, France & MONTPELLIER, France--()--Regulatory News:

Theradiag (Paris:ALTER) (ISIN: FR0004197747, ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, is today announcing further progress in bringing its LISA TRACKER® monitoring tests to the US market as part of its agreement with Miraca Life Sciences.

The Simponi® (golimumab) monitoring kit supplements the InformTxTM range and increases to six the number of tests available in the US market for biotherapies treating inflammatory bowel disease (IBD).

Miraca Life Sciences is the only company offering the Cimzia®, Stelara® and Simponi® monitoring, and it now has the most extensive monitoring range in the US market.

"We are very pleased to be adding a sixth test to the range of tests we are offering in the US market through our partnership with Miraca Life Sciences. The speed with which the range is expanding is very good news, and shows that there is currently a high level of unmet medical need. Based on this development we are expecting our US revenues to make an important contribution to Theradiag's overall sales growth in 2017," concluded Michel Finance, CEO at Theradiag.

Next financial press release:

First-quarter 2017 revenue: Thursday, April 27, 2017 (after the market close)

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 75 employees.

For more information about Theradiag, please visit our website: www.theradiag.com

Contacts

Theradiag
Investor Relations
Fabienne François, +33 (0)1 64 62 10 12
CFO
contact@theradiag.com
or
NewCap
Financial Communications & Investor Relations
Valentine Brouchot, +33 (0)1 44 71 94 94
theradiag@newcap.eu
or
Alize RP
Press Relations
Caroline Carmagnol, +33 (0)1 44 54 36 64
theradiag@alizerp.com

Contacts

Theradiag
Investor Relations
Fabienne François, +33 (0)1 64 62 10 12
CFO
contact@theradiag.com
or
NewCap
Financial Communications & Investor Relations
Valentine Brouchot, +33 (0)1 44 71 94 94
theradiag@newcap.eu
or
Alize RP
Press Relations
Caroline Carmagnol, +33 (0)1 44 54 36 64
theradiag@alizerp.com